The entire 36-week data for the remaining subjects in the trial is anticipated in the second quarter of this year.

Diabetes can influence more than just your blood sugar levels It can also affect multiple organs in the body including the ...

Surrozen said despite SZN-043 demonstrating changes in liver function assays, there was not enough clinical benefit for ...

Additionally, the prognosis of macular edema may help clinicians evaluate renal function, investigators reported ...

Ocugen has received approval from the DSMB to begin dosing the second cohort of patients in a trial of OCU200 for diabetic ...

Regeneron Pharmaceuticals has reported positive outcomes from the Phase III QUASAR trial of Eylea HD (aflibercept) 8mg injection in treating individuals with macular oedema following retinal vein ...

It is important to consider the relative efficacy of the available therapies for RVO with published data. This systematic review was therefore performed to assess the efficacy and safety of ...

Further information Decision makers noted that Aflibercept 8mg is clinically equivalent and of at least equal cost-effectiveness to the NICE recommended aflibercept 2mg formulation (TA 346 and TA294).